[go: up one dir, main page]

DE60328408D1 - Impfstoff - Google Patents

Impfstoff

Info

Publication number
DE60328408D1
DE60328408D1 DE60328408T DE60328408T DE60328408D1 DE 60328408 D1 DE60328408 D1 DE 60328408D1 DE 60328408 T DE60328408 T DE 60328408T DE 60328408 T DE60328408 T DE 60328408T DE 60328408 D1 DE60328408 D1 DE 60328408D1
Authority
DE
Germany
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328408T
Other languages
English (en)
Inventor
Peter Franz Ertl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60328408D1 publication Critical patent/DE60328408D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60328408T 2002-11-05 2003-11-03 Impfstoff Expired - Lifetime DE60328408D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0225786.3A GB0225786D0 (en) 2002-11-05 2002-11-05 Vaccine
PCT/EP2003/012429 WO2004041851A2 (en) 2002-11-05 2003-11-03 Vaccine

Publications (1)

Publication Number Publication Date
DE60328408D1 true DE60328408D1 (de) 2009-08-27

Family

ID=9947245

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328408T Expired - Lifetime DE60328408D1 (de) 2002-11-05 2003-11-03 Impfstoff

Country Status (11)

Country Link
US (2) US20060142221A1 (de)
EP (1) EP1558635B1 (de)
JP (1) JP2006519585A (de)
AR (1) AR041765A1 (de)
AU (1) AU2003285320A1 (de)
CA (1) CA2505208A1 (de)
DE (1) DE60328408D1 (de)
ES (1) ES2328685T3 (de)
GB (1) GB0225786D0 (de)
TW (1) TW200502245A (de)
WO (1) WO2004041851A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US8206950B2 (en) 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1880012B1 (de) * 2005-05-12 2015-07-08 Glaxo Group Limited Impfstoffzusammensetzung
GB0526210D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
RU2012140691A (ru) * 2009-03-13 2014-03-27 Лентиген Корпорейшен Вакцины на основе неинтегрирующегося ретровирусного вектора
WO2011043830A2 (en) * 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
EP2566884A2 (de) * 2010-05-07 2013-03-13 Duke University Genetische signaturen in hiv-1-hüllen-glycoproteinen vom untertyp c
US20120121633A1 (en) * 2010-07-16 2012-05-17 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
US10174317B2 (en) 2014-02-13 2019-01-08 Synthetic Genomics, Inc. Recombinant RNA particles and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0172970B1 (ko) * 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
AU2517895A (en) * 1994-05-20 1995-12-18 Microgenesys, Inc. Hiv polyprotein immunogens
WO1998041536A1 (en) * 1997-03-14 1998-09-24 President And Fellows Of Harvard College Glycosylation deficient siv and hiv envelope glycoproteins
WO2001027291A1 (en) * 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US20030158134A1 (en) * 2000-01-31 2003-08-21 Gerald Voss Vaccine for the prophylactic or therapeutic immunization against hiv
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
EP2065468A1 (de) * 2000-08-14 2009-06-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifikationen von HIV Env zur Erweiterung der Immunogenität zur Genimmunisierung
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
AU2003285320A8 (en) 2004-06-07
WO2004041851A2 (en) 2004-05-21
TW200502245A (en) 2005-01-16
JP2006519585A (ja) 2006-08-31
WO2004041851A3 (en) 2005-03-17
CA2505208A1 (en) 2004-05-21
AR041765A1 (es) 2005-05-26
EP1558635A2 (de) 2005-08-03
US20060142221A1 (en) 2006-06-29
ES2328685T3 (es) 2009-11-17
GB0225786D0 (en) 2002-12-11
AU2003285320A1 (en) 2004-06-07
US20070248679A1 (en) 2007-10-25
EP1558635B1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
IS7547A (is) Ónæmisvaldandi samsetningar
NO20050132D0 (no) Vaksinesammensetning
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE427876T1 (de) Luftkissenboot
DE50212360D1 (de) Anfahrhilfesteuerungsvorrichtung
DE50212349D1 (de) Hirurgie
DK1427444T3 (da) West-nil-vaccine
DE50301200D1 (de) Wischblatt
IS7831A (is) Bóluefni
NO20033882D0 (no) Vaksine
IS8325A (is) Bóluefni
DE60328408D1 (de) Impfstoff
ATA1572002A (de) Managementspleisskassette
DE50302660D1 (de) Stopfmachine
DE50301960D1 (de) Hydrolager
DE50301464D1 (de) Schraubensicherung
ATA4142004A (de) Trägerverbau
NO20051561D0 (no) Vaksine
ATE469773T1 (de) Zugöse
DE50303317D1 (de) Einschub-leistungsschalter
ATA19152002A (de) Hubkupplung
DE50209283D1 (de) Tropfbewässerungsrohr
ATE396192T1 (de) N-sulfonylaminothiazole
DE60320425D1 (de) Ostertagia-impfstoff
DE10244834B8 (de) Suszeptometer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition